TSCAN THERAPEUTICS IN
1.2800
19-May-25 14:12:27
15 minutes delayed
Stocks
+0.0400
+3.23%
Today's range
1.1850 - 1.3000
ISIN
N/A
Source
NASDAQ
-
13 Dec 2021 08:16:14 By Nasdaq GlobeNewswire
-
03 Dec 2021 06:00:00 By Nasdaq GlobeNewswire
-
TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies
02 Dec 2021 06:00:01 By Nasdaq GlobeNewswire
-
TScan Therapeutics to Participate in Upcoming Investor Conferences
11 Nov 2021 06:00:01 By Nasdaq GlobeNewswire
-
10 Nov 2021 06:00:02 By Nasdaq GlobeNewswire
-
04 Nov 2021 08:30:32 By Nasdaq GlobeNewswire
-
TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations
05 Oct 2021 06:00:01 By Nasdaq GlobeNewswire
-
TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference
28 Sep 2021 06:00:00 By Nasdaq GlobeNewswire
-
TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer
09 Sep 2021 15:05:00 By Nasdaq GlobeNewswire
-
TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
02 Sep 2021 06:00:01 By Nasdaq GlobeNewswire
-
19 Aug 2021 06:00:01 By Nasdaq GlobeNewswire
-
21 Jul 2021 06:00:01 By Nasdaq GlobeNewswire
-
TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering
15 Jul 2021 17:59:22 By Nasdaq GlobeNewswire